Erlotinib

COMPOSITION:

Each film-coated tablet contains Erlotinib hydrochloride 163.9 mg equivalent to Erlotinib…………………150mg.

INDICATIONS

LuciErlo is a kinase inhibitor indicated for:

• Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations who have progressed after at least one prior chemotherapy regimen, receiving first-line, maintenance, or second-line or higher therapy.

• In combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

DOSAGE AND USE:

• NSCLC: 150 mg orally, on an empty stomach, once daily.

• Pancreatic cancer: 100 mg orally, on an empty stomach, once daily.

STORAGE:

In a dry place and store at 20℃ to 25℃.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNINGS:

Keep medicine out of reach of Children. Do not administer LuciErlo during Pregnancy and Lactation.